Table 1.

Effect of the p38 MAPK inhibitor SB202190 on ouabain-induced CD69 upregulation in human monocytes

Treatment	CD69+ monocytes (means ± SEM)
Control	17.51 ± 3.04
Ouabain 100 nM	41.19 ± 7.58*
SB202190	23.19 ± 7.40
SB202190 + ouabain 100 nM	38.80 ± 7.79*

Notes: Monocytes were maintained for adhesion in culture for 2 hours and then incubated with 100 nM ouabain for 24 hours, in the presence or absence of the p38 MAPK inhibitor SB202190 (used at 20 µM). Values refer to the percentage of large monocytes in each condition ± standard error of mean (SEM);

^*statistical difference from the respective controls (P < 0.05, paired t-test). These experiments were performed using six individuals.